霉酚酸酯在标准治疗应答不佳的自身免疫性肝炎患者中的疗效与安全性
这项回顾性研究纳入105例标准治疗应答不佳或不耐受的自身免疫性肝炎患者,经霉酚酸酯挽救治疗后60%获得生化缓解,中位治疗12周;3例(2.7%)发生严重不良事件包括1例死亡,10例(9.2%)因不良事件停药。
要点
- 霉酚酸酯挽救治疗使60%患者在中位12周获得生化缓解。
- 标准治疗无应答者缓解率57%,不耐受者62%。
- 肝硬化患者缓解率47%,非肝硬化患者6%(P = .07)。
核心结论
- 在这项回顾性研究中,霉酚酸酯作为自身免疫性肝炎挽救治疗耐受性良好且中度有效,60%受试者获得生化缓解。
- 肝硬化患者缓解率更低、感染率更高,作者认为该人群需开展前瞻性研究。
研究设计与样本
- 回顾性研究,纳入105例标准治疗应答不佳或不耐受后接受霉酚酸酯治疗的自身免疫性肝炎患者。
- 98%患者接受糖皮质激素联合硫嘌呤类药物方案治疗。
- 患者经澳大利亚肝病协会临床研究网络从17家肝病门诊招募。
主要发现
- 霉酚酸酯治疗指征为治疗无应答者占40%,治疗不耐受者占60%。
- 63例(60%)在中位12周霉酚酸酯治疗后获得生化缓解。
- 无应答者缓解率57%,不耐受者缓解率62%。
- 肝硬化患者缓解率47%,非肝硬化患者6%(P = .07)。
- 3例(2.7%)发生严重不良事件包括1例死亡,10例(9.2%)因不良事件停用霉酚酸酯。
关键数值与推荐
- 生化缓解定义为丙氨酸和天冬氨酸转移酶水平及IgG水平在正常参考范围内,伴或不伴治疗前2年内正常肝组织学。
- 主要结局为生化缓解。
临床怎么用
- 作者认为霉酚酸酯可作为自身免疫性肝炎标准治疗应答不佳或不耐受后的挽救治疗,60%受试者获得生化缓解。
- 作者指出肝硬化患者缓解率更低、感染率更高,并认为该人群需开展前瞻性研究。
局限性
- 本研究为回顾性研究。
- 作者结论指出肝硬化患者需开展前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about outcomes of patients with autoimmune hepatitis (AIH) who have a suboptimal outcome to standard therapy and are then given mycophenolate mofetil as rescue therapy. We evaluated the efficacy and safety of mycophenolate mofetil in patients failed by or intolerant to corticosteroids, with or without azathioprine. METHODS: We performed a retrospective study of 105 patients with AIH who received mycophenolate mofetil therapy after an inadequate response or intolerance to standard therapy (98% received combination therapy with corticosteroids plus thiopurines). Patients were recruited from 17 liver clinics via the Australian Liver Association Clinical Research Network. We reviewed records for baseline demographic features and characteristics of liver disease, initial therapy, mycophenolate mofetil indications, treatment outcome, and side effects. The primary outcome was biochemical remission, defined as levels of alanine and aspartate transferase and IgG level within the normal reference range, with or without normal liver histology within the first 2 years of treatment. RESULTS: The indication for mycophenolate mofetil therapy was non-response to treatment for 40% of cases and intolerance to therapy for 60%. Overall, 63 patients (60%) achieved biochemical remission following a median 12 weeks treatment with mycophenolate mofetil. The proportion of patients who achieved biochemical remission was similar between patients receiving mycophenolate mofetil for non-response to standard therapy (57%) and patients with intolerance to standard therapy (62%). However, a lower proportion of patients with cirrhosis achieved biochemical remission (47%) than patients without cirrhosis (6%) (P = .07). Serious adverse events occurred in 3 patients (2.7%) including 1 death, and 10 patients (9.2%) discontinued mycophenolate mofetil because of adverse events. CONCLUSION: In this retrospective study of patients with AIH who received mycophenolate mofetil as a rescue therapy, we found the drug to be well tolerated and moderately effective, inducing biochemical remission in 60% of subjects. Rates of response are lower and rates of infection are higher in patients with AIH and cirrhosis. Prospective studies of mycophenolate mofetil are warranted for this population.
引用
- Roberts SK, Lim R, Strasser S, et al. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Clin Gastroenterol Hepatol. 2017. PMID: 29050991. doi:10.1016/j.cgh.2017.09.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。